Journal of Clinical Endocrinology & Metabolism, Vol 71, 391-397, Copyright © 1990 by Endocrine Society

ARTICLES

Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group

G Sassolas, AG Harris and A James-Deidier
Nuclear Medicine Center, Lyon, France.

Fifty-eight acromegalic patients were included in a multicenter prospective study of increasing doses (300-1500 micrograms) of SMS 201- 995 (octreotide, Sandostatin) administered 3 times daily, sc, during 6 months to determine its effect on signs and symptoms of GH hypersecretion. Subsequently, 34 of the patients were maintained for 12- 26 months on the minimal efficacious dose, determined from the previous dose-response study. Some adverse effects were frequently encountered, mostly at the initiation of treatment, and disappeared with time. Asymptomatic gallstones occurred in 5 patients. Minimal changes in carbohydrate tolerance, consisting of a rise in blood glucose and a transient decrease in plasma insulin level after meals, were noted. GH normalized in 22% of the patients, improved in 56%, and remained unchanged in 22% regardless of the dose. The optimal daily dose was 300 micrograms in 50% of the patients and 1500 micrograms in 20%. Pituitary tumor size reduction occurred in 47% of the patients harboring large tumors or tumor remnants. No additional improvement or escape from being controlled occurred with time. These data indicate that SMS 201- 995 is an effective treatment for refractory acromegaly and for some de novo patients for whom surgical therapy is not advisable.

This article has been cited by other articles:

				P. U. Freda, L. Katznelson, A. J. van der Lely, C. M. Reyes, S. Zhao, and D. Rabinowitz Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4465 - 4473. [Abstract] [Full Text] [PDF]

				L A Thomas, M J Veysey, G M Murphy, D Russell-Jones, G L French, J A H Wass, and R H Dowling Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly Gut, May 1, 2005; 54(5): 630 - 635. [Abstract] [Full Text] [PDF]

				J. S. Bevan The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1856 - 1863. [Abstract] [Full Text] [PDF]

				A. Saveanu, E. Lavaque, G. Gunz, A. Barlier, S. Kim, J. E. Taylor, M. D. Culler, A. Enjalbert, and P. Jaquet Demonstration of Enhanced Potency of a Chimeric Somatostatin-Dopamine Molecule, BIM-23A387, in Suppressing Growth Hormone and Prolactin Secretion from Human Pituitary Somatotroph Adenoma Cells J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5545 - 5552. [Abstract] [Full Text] [PDF]

				J. S. Bevan, S. L. Atkin, A. B. Atkinson, P.-M. Bouloux, F. Hanna, P. E. Harris, R. A. James, M. McConnell, G. A. Roberts, M. F. Scanlon, et al. Primary Medical Therapy for Acromegaly: An Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-Like Growth Factor-I, and Tumor Size J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4554 - 4563. [Abstract] [Full Text] [PDF]

				J. Ayuk, S. E. Stewart, P. M. Stewart, and M. C. Sheppard Long-Term Safety and Efficacy of Depot Long-Acting Somatostatin Analogs for the Treatment of Acromegaly J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4142 - 4146. [Abstract] [Full Text] [PDF]

				P. U. Freda Somatostatin Analogs in Acromegaly J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3013 - 3018. [Full Text] [PDF]

				Ph. Caron, A. Beckers, D. R. Cullen, M. I. Goth, B. Gutt, P. Laurberg, A. M. Pico, M. Valimaki, and W. Zgliczynski Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in the Management of Acromegaly J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 99 - 104. [Abstract] [Full Text] [PDF]

				M. Losa, E. Ciccarelli, P. Mortini, R. Barzaghi, D. Gaia, G. Faccani, M. Papotti, F. Mangili, M. R. Terreni, F. Camanni, et al. Effects of Octreotide Treatment on the Proliferation and Apoptotic Index of GH-Secreting Pituitary Adenomas J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5194 - 5200. [Abstract] [Full Text] [PDF]

				E. Ballare, L. Persani, A. G. Lania, M. Filopanti, E. Giammona, S. Corbetta, S. Mantovani, M. Arosio, P. Beck-Peccoz, G. Faglia, et al. Mutation of Somatostatin Receptor Type 5 in an Acromegalic Patient Resistant to Somatostatin Analog Treatment J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3809 - 3814. [Abstract] [Full Text] [PDF]

				D. C. Danila, J. N. S. Haidar, X. Zhang, L. Katznelson, M. D. Culler, and A. Klibanski Somatostatin Receptor-Specific Analogs: Effects on Cell Proliferation and Growth Hormone Secretion in Human Somatotroph Tumors J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2976 - 2981. [Abstract] [Full Text] [PDF]

				A. Saveanu, G. Gunz, H. Dufour, P. Caron, F. Fina, L. Ouafik, M. D. Culler, J. P. Moreau, A. Enjalbert, and P. Jaquet BIM-23244, a Somatostatin Receptor Subtype 2- and 5-Selective Analog with Enhanced Efficacy in Suppressing Growth Hormone (GH) from Octreotide-Resistant Human GH-Secreting Adenomas J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 140 - 145. [Abstract] [Full Text]

				P. Jaquet, A. Saveanu, G. Gunz, F. Fina, A. J. Zamora, M. Grino, M. D. Culler, J. P. Moreau, A. Enjalbert, and L'H. Ouafik Human Somatostatin Receptor Subtypes in Acromegaly: Distinct Patterns of Messenger Ribonucleic Acid Expression and Hormone Suppression Identify Different Tumoral Phenotypes J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 781 - 792. [Abstract] [Full Text]

				M. R. DRANGE, N. R. FRAM, V. HERMAN-BONERT, and S. MELMED Pituitary Tumor Registry: A Novel Clinical Resource J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 168 - 174. [Abstract] [Full Text]

				C. B. Newman, S. Melmed, A. George, D. Torigian, M. Duhaney, P. Snyder, W. Young, A. Klibanski, M. E. Molitch, R. Gagel, et al. Octreotide as Primary Therapy for Acromegaly J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3034 - 3040. [Abstract] [Full Text]

				S. Melmed, I. Jackson, D. Kleinberg, and A. Klibanski Current Treatment Guidelines for Acromegaly J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2646 - 2652. [Abstract] [Full Text]

				R. D. Hoeldtke, G. G. Horvath, K. D. Bryner, and G. R. Hobbs Treatment of Orthostatic Hypotension with Midodrine and Octreotide J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 339 - 343. [Abstract] [Full Text]

				P. Caron, I. Morange-Ramos, M. Cogne, and P. Jaquet Three Year Follow-Up of Acromegalic Patients Treated with Intramuscular Slow-Release Lanreotide J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 18 - 22. [Abstract] [Full Text] [PDF]